TrialBMJ open2023

Long-term efficacy and safety of erenumab in Japanese patients with episodic and chronic migraine: results from a 28-week open-label treatment period of a randomised trial.

Koichi Hirata et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.